SEC Company Response from Arcutis Biotherapeutics, Inc. (ARQT) (CIK 0001787306) (ARQT) — Jan 28, 2020
Arcutis Biotherapeutics, Inc. (ARQT) (CIK 0001787306)
Date: Jan. 28, 2020 · CIK: 0001787306 · Accession: 0001193125-20-016867
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-39186, 333-235806
Letter
Arcutis Biotherapeutics, Inc.
2945 Townsgate Road, Suite 110
Westlake Village, CA 91361
January 28, 2020
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549
Attention: Julia Griffith
Dietrich King
Christine Torney
Angela Connell
Re: Arcutis Biotherapeutics, Inc. Registration Statement on Form S-1 (File No. 333-235806) originally filed January 6, 2020, as amended, and corresponding Registration Statement on Form 8-A (File No. 001-39186) filed January 21, 2020.
Requested Date: January 30, 2020
Requested Time: 4:00 PM Eastern Time
Ladies and Gentlemen:
Arcutis Biotherapeutics, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to declare the above-captioned Registration Statements on Form S-1 and Form 8-A effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Registrant hereby authorizes Robert A. Freedman or Julia Forbess, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
The Registrant requests that it be notified of such effectiveness by a telephone call to Mr. Freedman at (650) 335-7292 or, in his absence, Ms. Forbess at (415) 875-2420.
* * *
Sincerely,
ARCUTIS BIOTHERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Arcutis Biotherapeutics, Inc. 2945 Townsgate Road, Suite 110 Westlake Village, CA 91361 January 28, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Julia Griffith Dietrich King Christine Torney Angela Connell Re: Arcutis Biotherapeutics, Inc. Registration Statement on Form S-1 (File No. 333-235806) originally filed January 6, 2020, as amended, and corresponding Registration Statement on Form 8-A (File No. 001-39186) filed January 21, 2020. Requested Date: January 30, 2020 Requested Time: 4:00 PM Eastern Time Ladies and Gentlemen: Arcutis Biotherapeutics, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to declare the above-captioned Registration Statements on Form S-1 and Form 8-A effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable. The Registrant hereby authorizes Robert A. Freedman or Julia Forbess, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration. The Registrant requests that it be notified of such effectiveness by a telephone call to Mr. Freedman at (650) 335-7292 or, in his absence, Ms. Forbess at (415) 875-2420. * * * Sincerely, ARCUTIS BIOTHERAPEUTICS, INC. By: /s/ Todd Franklin Watanabe Todd Franklin Watanabe Chief Executive Officer cc: Todd Franklin Watanabe, Chief Executive Officer Arcutis Biotherapeutics, Inc. Robert A. Freedman, Esq. Matthew Rossiter, Esq. Fenwick & West LLP